-
-
-
-
-
-
-
Bristol Myers Squibb drug reduces multiple myeloma progression risk by 52%
-
-
-
-
-
-
-
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Reiterated at Neutral by Cantor Fitzgerald on Eliquis Outlook
-
-
-
-
-
-
-
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
-
-
-
-
-
-
-
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple
-
-
-
-
-
-
-
Bernstein Weighs In on Bristol-Myers Squibb (BMY) Ahead of H2 Critical Clinical Readouts
-
-
-
-
-
-
-
Bristol Myers Squibb strikes deal with US government on drug pricing
-
1,198,737 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

